Francine Gervais
Corporate Officer/Principal at McGill University
Francine Gervais active positions
| Companies | Position | Start | End |
|---|---|---|---|
| McGill University | Corporate Officer/Principal | - | - |
Career history of Francine Gervais
Former positions of Francine Gervais
| Companies | Position | Start | End |
|---|---|---|---|
| BELLUS HEALTH | Chief Tech/Sci/R&D Officer | - | - |
PainCeptor Pharma Corp.
 PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Corporate Officer/Principal | - | - |
Training of Francine Gervais
| University of Montréal | Doctorate Degree |
Statistics
International
| Canada | 5 |
Operational
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
PainCeptor Pharma Corp.
PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Health Technology |
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
- Stock Market
- Insiders
- Francine Gervais
- Experience
